

# Policy Review Committee Open Forum

Michael Hogue  
Speaker, APhA House of Delegates

Elizabeth Johnson  
Chair, 2018-19 APhA Policy Review Committee

# Webinar Information

- Dial-in and use access code and audio pin on your control panel to limit audio issues and background noise during the webinar
- Submit your comments/questions during the webinar using the chat box on your control panel or email [HOD@aphanet.org](mailto:HOD@aphanet.org)
- Select “raise hand” button to request to speak and you will be recognized by the moderator as time permits
- Note: all comments/questions will be shared on the HOD webpage as background information for Delegates
- This webinar is being recorded for future access on the House of Delegates webpage, [www.pharmacist.com/apha-house-delegates](http://www.pharmacist.com/apha-house-delegates)

# Webinar Information

- Webinar scheduled for 60 minutes
  - 10 minutes for overview
  - 30 minutes for discussion of content
  - 20 minutes for questions/general information
- Moderators will clarify issues, but will not engage in debate

# Policy Review Committee

**Elizabeth Johnson,**  
**Chair**  
Sacramento, CA

**Evan Colmenares**  
Durham, NC

**Michelle Cottino**  
Basking Ridge, NJ

**Zak Fettman**  
Cincinnati, OH

**G. Lawrence Hogue**  
Westminster, MD

**James Kirby**  
Cincinnati, OH

**Monty McMinn**  
Mineral Wells, TX

**Jeff Neigh**  
Annandale, VA


**Anjoli Punjabi**  
St. Paul, MN

**Brent Reed**  
Baltimore, MD

**Veronica Vernon**  
Indianapolis, IN

# Policy Process Roadmap

*Transforming Ideas into Action*



# Current Policy Information

## Policy Manual

- Online searchable database:
  - <http://www.pharmacist.com/policy-manual>
- Online PDF version:
  - <http://pharmacist.com/sites/default/files/files/16898%20CURRENT%20ADOPTED%20POLICY%20MANUAL%20-%20FINAL.pdf>

# 2019 House of Delegates

## Committee of the Whole

- Delegates & Non-delegates may speak
- Open discussion

## House considers PRC report

- Single vote cast by Delegates to pass complete report or suggested items are pulled from the full report
- Single vote cast to pass remaining recommendations
- Any items pulled from the full report are voted on separately

Other specific recommendations pulled from the full report will be discussed separately

# 2019 Potential Recommendations

- Retain
- Amend
- Archive
- Rescind



Reviewed **93** policy statements

- **Recommend to Retain – 80**
- **Recommend to Amend – 3**
- **Recommend to Archive – 15**
- **Recommend to Rescind – none**

**98** Total Recommendations for Action by the House

# Policy Review Committee- **Amend**

## Recommend to Amend – ITEM #81

### 1990 Federal Funding to Evaluate the Impact of Health Care Policies

1. APhA supports the study of economic, scientific, and social issues related to health care, particularly pharmaceutical services.
2. APhA urges the federal government to establish funding mechanisms for objective research to assess the impact of public policy on the health care system, particularly pharmaceutical services.
3. APhA urges that all federally-funded research addressing public policy pertaining to pharmaceutical services incorporate input from ~~organized~~ the pharmacy profession.

# Policy Review Committee- **Amend**

## Recommend to Amend – ITEM #82

### 2005, 1990 Use of Representative Populations in Clinical Studies

1. APhA supports the use of representative populations in clinical studies, including, but not limited to protected populations such as ~~the use of~~ women, minorities, the elderly, transgender individuals, and children when appropriate.
2. APhA encourages the development of research techniques which would identify possible problems not readily detected in adult clinical investigations to aid in the safe and effective evaluation of drugs in children.

# Policy Review Committee- **Amend**

## Recommend to Amend – ITEM #83

### 2016 Substance Use Disorder

1. APhA supports legislative, regulatory, and private sector efforts that include pharmacists' input and that will balance patient-consumers' need for access to medications for legitimate medical purposes with the need to prevent the diversion, misuse, and abuse of medications.
2. APhA supports consumer sales limits of nonprescription drug products, such as methamphetamine precursors, that may be illegally converted into drugs for illicit use.
3. APhA encourages education of all personnel involved in the distribution chain of nonprescription products so they understand the potential for certain products, such as methamphetamine precursors, to be illegally converted into drugs for illicit use. ~~APhA supports patient-consumer education of consequences of methamphetamine use, misuse, and abuse.~~ APhA supports comprehensive substance use disorder education, prevention, treatment, and recovery programs.
4. APhA supports public and private initiatives to fund treatment and prevention of substance use disorders.
5. APhA supports stringent enforcement of criminal laws against individuals who engage in drug trafficking.

# Policy Review Committee- **Amend**

Recommend to Amend

**1990 Federal Funding to Evaluate the Impact of Healthcare Policies**

**2005, 1990 Use of Representative Populations in Clinical Studies**

**2016 Substance Use Disorder**

***Time for Discussion***

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #84

### 2005, 2002 Emergency Preparedness

APhA supports the continuing efforts of the Joint Commission of Pharmacy Practitioners working group on emergency preparedness and response to network with the Office of Homeland Security and with any other relevant governmental and/or military agency.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #85

### 2014, 2005, 1986 Pharmacists' Responsibilities in Community Medication Awareness Programs

1. APhA supports the development of comprehensive educational programs on the proper use and safe and environmentally responsible disposal of prescription and nonprescription medication.
2. Pharmacists should take a major educational responsibility in proactive programs which optimize therapeutic outcomes and minimize risks from inappropriate medication use.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #86

### 1987 Future of Pharmacy

1. APhA supports programs which plan for the future of pharmacy.
2. APhA supports programs which encourage innovations in the practice of pharmacy in a changing health care environment.
3. APhA supports programs which reflect a positive image of pharmacists.



# Policy Review Committee – Archive

Recommend to Archive – ITEM #87

## 1966 APhA Study Proposal

APhA should expand its research programs and plans to help the profession find solutions to its problems, discover new opportunities for service, and improve its present practices.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #88

### 2012, 2007, 2001, 1995 Impact of the Pharmacists' Working Conditions on Public Safety

1. APhA recognizes that the quality of a pharmacist's work-life affects public safety and that a working environment conducive to providing effective patient care is essential.
2. APhA opposes the practice of imposing minimum numbers of prescriptions which pharmacists are to dispense in a given period of time. Further, APhA opposes employment practices that evaluate a pharmacist's performance on the basis of set quotas of work performed.
3. APhA opposes employment practices that limit a pharmacist's ability to provide effective patient care.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #89

### 2001 ~~Work Schedules~~ Employee Benefits

1. APhA supports a work environment in which innovative work schedules are available to pharmacists and encourages employers to allow meal breaks and rest periods.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #90

### 2010 Pharmacogenomics/Personalized Medicine

1. APhA supports evidence-based personalized medicine, defined as the use of a person's clinical, genetic, genomic, and environmental information to select a medication or its dose, to choose a therapy, or to recommend preventive measures, as a means to improve patient safety and optimize health outcomes.
2. APhA promotes pharmacists as health care providers in the collection, use, interpretation, and application of pharmacogenomics data to optimize health outcomes.
3. APhA supports the development and implementation of programs, tools, and clinical guidelines that facilitate the translation and application of pharmacogenomics data into clinical practice.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #91

### 2005, 2000 Pharmacogenomics

1. Recognizing the benefits and risks of pharmacogenomics and applications of this technology, APhA supports further research and assessment of the clinical, economic, and humanistic impact of pharmacogenomics on the health care system. This includes collaboration with other health care and consumer organizations for information sharing and development of pharmaceutical care processes involving these therapies. Pharmacogenomics is defined as the application of genomic technology in drug development and therapy.
2. APhA supports ongoing vigilance by all individuals and organizations with access to genetic information to maintain the confidentiality of the information.
3. APhA supports the development of educational materials to train and educate pharmacists, student pharmacists, pharmacy technicians, and consumers regarding pharmacogenomics.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #92

### 2004, 1965 Mental Health Programs

APhA supports pharmacists' participation in the development and implementation of all aspects of mental health programs so that the special needs and problems of the mentally ill can be effectively met.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #93

### 2003 Drug Addiction/Chemical Dependency Education

APhA urges pharmacists and student pharmacists~~students~~ to become educated in the recognition and treatment of drug addiction and chemical dependency.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #94

### 2005, 1993 HIV/AIDS Education

1. APhA encourages pharmacists and student pharmacists to become more knowledgeable about HIV/AIDS.
2. APhA supports the development of cooperative efforts among health care organizations and agencies to facilitate the collection, evaluation, and distribution of information on HIV/AIDS.
3. APhA supports the development of educational programs for pharmacists and student pharmacists that would enable them to assume a service role in the prevention and treatment of HIV/AIDS.



# Policy Review Committee – Archive

## Recommend to Archive – ITEM #95

### 1994 Preventing Dispensing-Related Problems

1. APhA encourages the development of practice guidelines to identify, resolve, and prevent dispensing-related problems.
2. APhA supports the development of electronic systems that confidentially collect information to record dispensing-related problems.
3. APhA believes that pharmacists have a professional responsibility to document and report dispensing-related problems in an ongoing effort to improve the quality of the drug distribution system.
4. APhA will assume a leadership role in the gathering, analysis, and interpretation of the aggregate data regarding dispensing-related problems, and the dissemination of the results, which will enable pharmacists to further improve medication distribution.

# Policy Review Committee – Archive

## Recommend to Archive – ITEM #96

### 2005, 1968 Cigarette Sales in Pharmacies

APhA recommends that pharmacists not allow smoking in their prescription departments.

# Policy Review Committee – Archive

Recommend to Archive – ITEM #97

## 2014 The Use and Sale of Electronic Cigarettes (e-cigarettes)

4. APhA urges the FDA to require the full disclosure of all ingredients in e-cigarettes and other vaporized nicotine products in both the pre-use and vapor states.

# Policy Review Committee – Archive

Recommend to Archive – ITEM #98

2005, 1990 Needle/Syringe Exchange Programs in the Prevention ~~of the Spread of Blood-Borne Infectious Diseases Human Immunodeficiency Virus (HIV) and Other Infections~~

2. APhA supports the objective gathering and analysis of data and information about the effectiveness of pilot needle/syringe exchange programs in preventing the spread of HIV and other blood-borne infectious diseases.

# Policy Review Committee – Archive

Recommend to Archive

2005, 2002 Emergency Preparedness

2014, 2005, 1986 Pharmacists' Responsibilities in Community Medication Awareness Programs

1987 Future of Pharmacy

1966 APhA Study Proposal

2012, 2007, 2001, 1995 Impact of the Pharmacists' Working Conditions on Public Safety

2001 ~~Work Schedules~~ Employee Benefits

2010 Pharmacogenomics/Personalized Medicine

2005, 2000 Pharmacogenomics

2004, 1965 Mental Health Programs

2003 Drug Addiction/Chemical Dependency Education

2005, 1993 HIV/AIDS Education

1994 Preventing Dispensing-Related Problems

2005, 1968 Cigarette Sales in Pharmacies

2014 The Use and Sale of Electronic Cigarettes (e-cigarettes)

2005, 1990 Needle/Syringe Exchange Programs in the Prevention of ~~the Spread of~~ Blood-Borne Infectious Diseases ~~Human Immunodeficiency Virus (HIV) and Other Infections~~

*Time for Discussion*

## Policy Review Committee –

### Additional Review Recommendations

(#48) 2001 Administrative Contributions to Medication Errors

(#49) 1991 Emerging Technologies

(#50) 1991 Pharmaceutical Care and the Provision of Cognitive Services with Technologies

(#51) 2005, 1993 Documentation

(#52) 1994 Implications of On-line Prospective DUR on the Application of Pharmacists' Scientific and Clinical Judgments

(#53) 2004 Automation and Technology in Pharmacy Practice

(#54) 2015 Interoperability of Communications Among Health Care Providers to Improve Quality of Patient Care

(#55) 2009 Health Information Technology

## Policy Review Committee –

### Additional Review Recommendations

(#64) 20015, 1970 Medicare, Medicaid, and Other Third-party Payment Programs

(#65) 2005, 1969 Medicare: Reimbursement Procedures

(#66) 1969 Medicare Task Force: Policy Guidelines

(#67) 1967 Drugs Provided Under Social Security Act: Guidelines for Pharmaceutical Service

(#68) 2005, 1975 Periodic Adjustments of Professional Fees in Federal programs

# Policy Review Committee – Report

## Overall Discussion

- ***Retain***
  - 80 statements
- ***Amend***
  - 3 statements
- ***Archive***
  - 15 statements
- ***Rescind***
  - 0 statements

***Time for Discussion***



# House Keeping

**New Business Items are due February 20, 2019**

House Committee reports available at [www.pharmacist.com/apha-house-delegates](http://www.pharmacist.com/apha-house-delegates)

Contact your state association or recognized national organization to secure your Delegate seat

- All Delegate materials will be sent electronically this year
- *A limited number* of Delegate books will be available onsite

## **Policy Review Committee Webinars**

**February 6, 6:00 – 7:30pm (ET)**

## **New Business Item Webinars**

**February 27, 12:00 – 1:30pm (ET)**


**March 6, 6:00 – 7:30pm (ET)**

# Continue the Conversation

## Visit APhA Engage

APhA Engage makes joining the conversation easy!

1. Visit [engage.pharmacist.com](https://engage.pharmacist.com)
2. Login using your APhA username and password
3. Click “Participate” then “Join a Community”
4. Find one of the three the “HOD Issue” communities
5. Click “Join” and follow the prompts on your screen



# 2019 House of Delegates

## House of Delegates First Session

Friday, March 22, 3:00 to 5:00pm

## New Business Review Committee Open Hearing

Saturday, March 23, 1:00 to 2:30pm

## Policy Committee Open Hearing

Sunday, March 24, 1:00 to 3:00pm

## House of Delegates Final Session

Monday, March 25, 1:30 to 4:30pm

# Ideas for Future Policy Topics

Are there topics we should consider for the 2020 House of Delegates?

- **These are topics needing more development than through the new business process**
- **Tell us now or send to [HOD@aphanet.org](mailto:HOD@aphanet.org)**

# Policy Review Committee Open Forum

Thank you for your time and attention!

[www.pharmacist.com/apha-house-delegates](http://www.pharmacist.com/apha-house-delegates)

[HOD@aphanet.org](mailto:HOD@aphanet.org)